Other antipsychotics

Abilify

Approved 10 Dec 2004OralSolution

The FDA lists this product in 12 strengths and forms.

Official labelAsk Osler about it

Composition

Active ingredients: ARIPIPRAZOLE 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Strengths and forms

The FDA lists each strength of a product separately; these pages share one label.

ARIPIPRAZOLE 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SolutionThis page
ARIPIPRAZOLE 9.75MG/1.3ML (7.5MG/ML) · InjectableNDA021866-001 · Discontinued
ARIPIPRAZOLE 2MG · TabletNDA021436-006 · Prescription
ARIPIPRAZOLE 30MG · TabletNDA021436-004 · Prescription
ARIPIPRAZOLE 15MG · TabletNDA021436-002 · Prescription
ARIPIPRAZOLE 5MG · TabletNDA021436-005 · Prescription
ARIPIPRAZOLE 20MG · TabletNDA021436-003 · Prescription
ARIPIPRAZOLE 10MG · TabletNDA021436-001 · Prescription
ARIPIPRAZOLE 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet, orally disintegratingNDA021729-005 · Discontinued
ARIPIPRAZOLE 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet, orally disintegrating

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

NDA021729-003 · Discontinued

ARIPIPRAZOLE 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet, orally disintegratingNDA021729-004 · Discontinued

ARIPIPRAZOLE 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet, orally disintegratingNDA021729-002 · Discontinued

Official product information

Drugs@FDA lists the approved labels, letters and reviews for application NDA021713.

Open Drugs@FDA

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.